Trial · NCT02536664
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Were Alive and Free From Progressive Disease | First-line Stratum | 88.28 | 95% Confidence Interval 83.97 to 92.59 | percentage of participants | |
| Percentage of Participants Who Were Alive and Free From Progressive Disease | Relapsed/Refractory Stratum | 76.03 | 95% Confidence Interval 68.79 to 83.28 | percentage of participants | |
| Median Progression Free Survival (PFS) Time | First-line Stratum | NA | 95% Confidence Interval NA to NA | months | |
| Median Progression Free Survival (PFS) Time | Relapsed/Refractory Stratum | NA | 95% Confidence Interval NA to NA | months | |
| Percentage of Participants Who Were Alive | First-line Stratum | 96.89 | 95% Confidence Interval 94.69 to 99.09 | percentage of participants | |
| Percentage of Participants Who Were Alive | Relapsed/Refractory Stratum | 95.44 | 95% Confidence Interval 91.81 to 99.07 | percentage of participants | |
| Median Overall Survival (OS) Time | First-line Stratum | NA | 95% Confidence Interval NA to NA | months | |
| Median Overall Survival (OS) Time | Relapsed/Refractory Stratum | NA | 95% Confidence Interval NA to NA | months | |
| Percentage of Participants With Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD] at the End of Maintenance Therapy | First-line Stratum | CR | 58.4 | percentage of participants | |
| Percentage of Participants With Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD] at the End of Maintenance Therapy | Relapsed/Refractory Stratum | CR | 51.2 | percentage of participants | |
| Percentage of Participants With Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD] at the End of Maintenance Therapy | First-line Stratum | PR | 21.0 | percentage of participants | |
| Percentage of Participants With Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD] at the End of Maintenance Therapy | Relapsed/Refractory Stratum | PR | 20.9 | percentage of participants | |
| Percentage of Participants With Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD] at the End of Maintenance Therapy | First-line Stratum | SD | 12.1 | percentage of participants | |
| Percentage of Participants With Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD] at the End of Maintenance Therapy | Relapsed/Refractory Stratum | SD | 9.3 | percentage of participants | |
| Percentage of Participants With Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD] at the End of Maintenance Therapy | First-line Stratum | PD | 8.5 | percentage of participants | |
| Percentage of Participants With Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD] at the End of Maintenance Therapy | Relapsed/Refractory Stratum | PD | 18.6 | percentage of participants | |
| Percentage of Participants With Best Overall Response | First-line Stratum | 98.4 | 95% Confidence Interval 96.9 to 99.8 | percentage of participants | |
| Percentage of Participants With Best Overall Response | Relapsed/Refractory Stratum | 96.5 | 95% Confidence Interval 93.8 to 99.3 | percentage of participants | |
| Percentage of Participants With Initiation of New Therapy | First-line Stratum | No data | 16.7 | percentage of participants | |
| Percentage of Participants With Initiation of New Therapy | Relapsed/Refractory Stratum | No data | 11.6 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02536664/results